And here’s where things get interesting for a cure-seeking diabetic: when scientists saw that cells were flooding islets…
Research
Faustman Lab Research: How Excited Should You Be?
Last week, diabetes headlines were dominated by a new study from the Faustman Lab at Massachusetts General Hospital, pub…
Treatment With Generic Vaccine May Temporarily Reverse Type 1 Diabetes
A phase I clinical trial, led by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital (MGH) Immunobi…
Immunomodulators for Treatment of Type 1 Diabetes: An Overview
In the 1980s, studies demonstrated that suppressing the immune system of people recently diagnosed with T1D reduced thei…
JDRF and Novo Nordisk to Collaborate on Type 1 Diabetes Immunotherapies Research
JDRF and Novo Nordisk have announced that they are partnering in an attempt to discover and develop novel immunotherapie…
Experimental Drug May Protect From Type 1 Diabetes
JDRF-funded researchers at Harvard School of Public Health have found that an experimental drug, called TUDCA, can drama…
Cebix Presents C-peptide Replacement Therapy Data
Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta(TM), the company's long-acti…
DiaPep277 Granted Orphan Drug Designation by FDA
The U.S. FDA has granted Orphan Drug designation for DiaPep277 for the treatment of type 1 diabetes (T1D) patients with …
Proving the Hygiene Hypothesis?
The hygiene hypothesis sounds plausible, especially in light of studies that have found increasing rates of diseases lik…
Kamada Announces Positive Preliminary Results for New Type 1 Diabetes Therapy
Kamada, announced positive preliminary interim results from a Phase I/II clinical trial of D1-AAT, which includes the Al…